Article

Alcaftadine approved for ocular itching

Alcaftadine ophthalmic solution 0.25% (Lastacaft, Vistakon) has been approved by the FDA for the prevention of itching associated with allergic conjunctivitis in patients aged more than 2 years.

Jacksonville, FL-Alcaftadine ophthalmic solution 0.25% (Lastacaft, Vistakon) has been approved by the FDA for the prevention of itching associated with allergic conjunctivitis in patients aged more than 2 years.

The H1 histamine receptor antagonist also inhibits the release of histamine from mast cells.

In clinical trials, the most common side effects were eye irritation, burning and/or stinging on instillation, eye redness, and eye itching. They occurred in less than 4% of alcaftadine-treated eyes.

The most common non-ocular side effects were nasopharyngitis, headache, and influenza. They occurred in less than 3% of patients with alcaftadine-treated eyes.

The ophthalmic solution is packaged in 5-ml bottles containing 3 ml alcaftadine 0.25% (2.5 mg/ml) preserved with benzalkonium chloride. The recommended dosage of alcaftadine is one drop in each eye once daily.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.